Clinical trials: Unknown Primary Neoplasms

Carcinoma of Unknown Primary

Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)

• Completed
• Age: 18 years and older
• Phase 2
• Injection or infusion
• Results posted

Abbreviated Title: Pembrolizumab in Patients with Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) Trial Phase: 2 Clinical Indication: Treatment naïve patients with poor prognosis carcinoma of unknown primary site Trial…

Trial name

CUP (NCT03391973)

Testing

Pembrolizumab Injection

Where

3 sites in Canada

Volunteers

33 people, healthy volunteers welcome

Sponsor

AHS Cancer Control Alberta